1 |
NCT03330795 |
Recruiting |
Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant |
- Primary Immunodeficiency
- PID
|
- Biological: CD3/CD19 neg allogeneic BMT
|
Interventional |
Phase 1 Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pittsburgh
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety: Transplant-Related Mortality
- Safety: Engraftment Failure
- Efficacy: Count of Participants with Absence of Severe Allograft Dysfunction
- (and 18 more...)
|
8 |
All |
10 Years to 45 Years (Child, Adult) |
NCT03330795 |
DAIT BOLT-BMT DAIT RTB-003 U01AI125050 |
BOLT-BMT |
November 21, 2017 |
November 2023 |
November 2024 |
November 6, 2017 |
November 24, 2017 |
|
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
|
2 |
NCT03300882 |
Recruiting |
PREDICT Cytomegalovirus (CMV) |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Clinical Trials in Organ Transplantation
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Time from CMV Prophylaxis Discontinuation Post-Transplant to First Detection of CMV Infection or CMV Disease within 6 months Post CMV Prophylaxis Discontinuation
- Time from CMV Prophylaxis Discontinuation Post-Transplant to First Detection of CMV Infection or CMV Disease Within 18 Months Post-Transplant
|
71 |
All |
18 Years and older (Adult, Senior) |
NCT03300882 |
DAIT CTOT-22 |
PREDICT CMV |
October 23, 2017 |
March 2020 |
March 2020 |
October 4, 2017 |
January 4, 2018 |
|
- Johns Hopkins Hospital: Transplantation
Baltimore, Maryland, United States - Duke University Medical Center: Transplantation
Durham, North Carolina, United States - Cleveland Clinic Foundation: Transplantation
Cleveland, Ohio, United States - Toronto General Hospital: Transplantation
Toronto, Canada
|
3 |
NCT02266888 |
Recruiting |
B Cell Induction in Pediatric Lung Transplantation |
|
- Biological: Rituximab (Rituxan®)
- Biological: Placebo
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Clinical Trials in Organ Transplantation in Children
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Earliest time to Chronic Allograft Dysfunction
- Earliest time to listing for retransplantation
- Time to Death
- (and 11 more...)
|
50 |
All |
up to 21 Years (Child, Adult) |
NCT02266888 |
DAIT CTOTC-08 |
|
October 2014 |
August 2019 |
August 2019 |
October 17, 2014 |
September 25, 2017 |
|
- Stanford University
Palo Alto, California, United States - Children's Hospital Boston
Boston, Massachusetts, United States - Washington University
Saint Louis, Missouri, United States - (and 4 more...)
|
4 |
NCT02631720 |
Recruiting |
CLAD Phenotype Specific Risk Factors and Mechanisms |
- Lung Transplant
- Post Lung Transplantation
|
- Procedure: Blood Draw
- Procedure: Bronchoscopy
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Clinical Trials in Organ Transplantation
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Time from transplant to Restrictive Chronic Lung Allograft Dysfunction (RCLAD) or Bronchiolitis Obliterans Syndrome (BOS).
- Chemokine/cytokine Quantification of Type 1 and Type 17 immune profile proteins
- Longitudinal Quality of life (QOL) trajectory
- (and 3 more...)
|
800 |
All |
18 Years and older (Adult, Senior) |
NCT02631720 |
DAIT CTOT-20 |
|
December 2015 |
October 2020 |
October 2020 |
December 16, 2015 |
December 26, 2017 |
|
- University of California, Los Angeles
Los Angeles, California, United States - Johns Hopkins University
Baltimore, Maryland, United States - Duke University
Durham, North Carolina, United States - (and 2 more...)
|
5 |
NCT02204202 |
Recruiting |
PET Assessment of Acute Lung Transplant Rejection |
|
- Drug: [18F]FDG
- Drug: [18F]ISO-1
|
Observational |
|
- Washington University School of Medicine
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Ki, the influx constant that describes the rate of [18F]FDG uptake, in the whole lung
- Logan plot analysis determined distribution volume ratio (DVR) of [18F] ISO-1 uptake
- Progesterone receptor membrane component 1 (PGRMC1) staining of biopsy tissues and bronchoalveolar lavage cells
|
60 |
All |
19 Years and older (Adult, Senior) |
NCT02204202 |
1R01HL121218-01 R01HL121218 |
|
February 2014 |
January 2018 |
January 2018 |
July 30, 2014 |
November 3, 2016 |
|
- Washington University School of Medicine / Barnes-Jewish Hospital
St. Louis, Missouri, United States
|
6 |
NCT01273207 |
Recruiting |
Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans |
- Bronchiolitis Obliterans
- Constructive Bronchiolitis
- Graft Versus Host Disease
|
- Drug: Inhaled Cyclosporine Solution
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary endpoints include the toxicity profile (adverse events) and efficacy of extended use CIS for BO/BOS
- Secondary endpoints include improvement in chest CT images, results of peripheral blood and bronchoalveolar cytokine arrays, and functional capacity measurements
- Toxicity profile (adverse events)
|
78 |
All |
10 Years to 80 Years (Child, Adult, Senior) |
NCT01273207 |
110064 11-H-0064 |
|
February 1, 2011 |
June 30, 2025 |
June 30, 2025 |
January 10, 2011 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
7 |
NCT03072589 |
Recruiting |
Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation |
|
- Drug: Regadenoson infusion
|
Interventional |
Phase 1 |
- Christine Lau, MD
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Virginia
|
Other / NIH |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient tolerability of assigned dose and duration
- Activation of iNKT cells
- Clinical Pulmonary Graft Dysfunction (PGD) score
- Inflammatory Cytokines in blood and bronchioalveolar lavage
|
21 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03072589 |
UVA-LAU-01 1R01HL128492-01A1 |
|
November 30, 2017 |
August 1, 2020 |
August 1, 2021 |
March 7, 2017 |
February 8, 2018 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
8 |
NCT03388008 |
Not yet recruiting |
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation |
- Lung Transplant Rejection
- Antibody-mediated Rejection
|
- Drug: Belatacept
- Drug: Tacrolimus
- Drug: ATG
- (and 3 more...)
|
Interventional |
Phase 2 |
- Ramsey Hachem
- National Heart, Lung, and Blood Institute (NHLBI)
- Bristol-Myers Squibb
- Washington University School of Medicine
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Donor-specific HLA antibodies, re-transplantation, or death
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03388008 |
Bela Lung Pilot |
|
June 1, 2018 |
January 31, 2021 |
April 30, 2021 |
January 2, 2018 |
January 2, 2018 |
|
- Baylor University Medical Center at Dallas
Dallas, Texas, United States
|
9 |
NCT02423070 |
Recruiting |
Genome Transplant Dynamics |
- Thoracic Organ Transplantation
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To validate the predictive accuracy and ROC characteristics of the percentage of circulating cell-free donor-derived DNA (%ccfdDNA) in a multicenter, prospective cohort study of heart-and lung-transplant patients, recruited through a consortium ...
- To compare %ccfdDNA characteristics in AMR (antibody-mediated rejection) and ACR (acute cellular rejection)
- To determine early immunologic changes associated with changes in %ccfdDNA
|
495 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02423070 |
999915115 15-H-N115 |
|
April 18, 2015 |
November 30, 2024 |
November 30, 2024 |
April 22, 2015 |
March 21, 2018 |
|
- MedStar Health Institutions
Washington, District of Columbia, United States - Johns Hopkins University
Baltimore, Maryland, United States - University of Maryland at Baltimore/MPRC
Catonsville, Maryland, United States - (and 2 more...)
|
10 |
NCT03150095 |
Not yet recruiting |
Health Coaching to Improve Self-Management in Thoracic Transplant Candidates |
- Self-management
- Lung Transplant
- Heart Transplant
|
- Behavioral: Health coaching
|
Interventional |
Not Applicable |
- Mayo Clinic
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in Score on Self-Management Ability Scale (SMAS-30)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03150095 |
17-003921 K23HL128859 |
|
July 2018 |
December 2019 |
July 2020 |
May 11, 2017 |
May 11, 2017 |
|
|
11 |
NCT01841307 |
Recruiting |
Cromolyn Detection of Silent Aspiration |
- Gastroesophageal Reflux
- Respiratory Aspiration
- Idiopathic Pulmonary Fibrosis
- Lung Transplantation
|
|
Interventional |
Phase 1 |
- University of California, San Francisco
- Aradign Corportation
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Total cromolyn in urine collected overnight
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01841307 |
13-11080 |
|
June 2014 |
April 2017 |
July 2017 |
April 26, 2013 |
August 12, 2016 |
|
- UCSF Airway Clinical Research Center
San Francisco, California, United States
|
12 |
NCT01799538 |
Recruiting |
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis |
|
- Drug: albuterol inhaler
- Procedure: PFT
- Drug: albuterol nebulizer
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Greater improvement in lung function with nebulized albuterol.
|
150 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT01799538 |
130051 13-H-0051 |
|
February 23, 2013 |
October 1, 2019 |
November 1, 2019 |
February 26, 2013 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
13 |
NCT00084305 |
Recruiting |
Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis |
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT00084305 |
040211 04-HG-0211 |
|
June 9, 2004 |
|
|
June 10, 2004 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
14 |
NCT02368340 |
Recruiting |
A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis |
- Hermansky Pudlak Syndrome
|
- Other: Pulmonary function test
- Other: Chest CT
- Other: Sample collection
|
Observational |
|
- Vanderbilt University
- University of South Florida
- National Institutes of Health (NIH)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Chest CT scan
- Pulmonary function test
|
150 |
All |
12 Years to 90 Years (Child, Adult, Senior) |
NCT02368340 |
150104 U54HL127672 |
|
March 2015 |
August 2020 |
August 2020 |
February 23, 2015 |
February 28, 2018 |
|
- Mayo Clinic - Florida
Jacksonville, Florida, United States - Loyola University Medical Center
Maywood, Illinois, United States - Brigham and Women's Hospital, Harvard
Boston, Massachusetts, United States - (and 3 more...)
|
15 |
NCT00552357 |
Recruiting |
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation |
- Primary Graft Dysfunction
- Lung Transplantation
|
|
Observational |
|
- University of Pennsylvania
- National Heart, Lung, and Blood Institute (NHLBI)
- Columbia University
- (and 8 more...)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Primary graft dysfunction, defined by the ISHLT criteria
|
1150 |
All |
13 Years to 68 Years (Child, Adult, Senior) |
NCT00552357 |
1417 R01HL087115-01A1 |
|
December 2007 |
June 2018 |
June 2018 |
November 1, 2007 |
March 13, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
16 |
NCT00457847 |
Recruiting |
Identifying Genetic Characteristics That Increase the Risk of Developing Primary Graft Dysfunction Following Lung Transplantation |
- Primary Graft Dysfunction
- Lung Transplantation
|
|
Observational |
|
- University of Pennsylvania
- National Heart, Lung, and Blood Institute (NHLBI)
- Columbia University
- (and 8 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Genetic factors that increase the risk of developing PGD
|
1150 |
All |
15 Years to 65 Years (Child, Adult) |
NCT00457847 |
1380 R01HL081619 |
|
February 2007 |
June 2018 |
June 2018 |
April 9, 2007 |
July 11, 2017 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
17 |
NCT02019641 |
Recruiting |
The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease |
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- Interstitial Pneumonitis
- Desquamative Interstitial Pneumonia
|
- Other: Aerobic Exercise Training
- Other: Education
|
Interventional |
Phase 2 |
- National Institutes of Health Clinical Center (CC)
- George Mason University
- Inova Fairfax Hospital
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 6MWT distance (most frequently used measured of physical performance for evaluating patients with ILD and other advanced lung diseases).
- Peak work rate on a treadmill cardiopulmonary exercise test and performance and perceived fatigability.
- Cardiorespiratory capacity, including AT-time and muscle oxygenation capacity.
- (and 2 more...)
|
60 |
All |
21 Years to 80 Years (Adult, Senior) |
NCT02019641 |
140027 14-CC-0027 |
|
December 20, 2013 |
December 31, 2020 |
December 31, 2021 |
December 24, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - INOVA Fairfax Hospital
Falls Church, Virginia, United States
|
18 |
NCT03173937 |
Recruiting |
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome |
- Severe Aplastic Anemia
- Hypo-Plastic MDS
- Myelodysplastic Syndrome (MDS)
|
|
Interventional |
Phase 1 Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cord engraftment
- Treatment related mortality (TRM), and standard transplant outcome variables such as non-hematologic toxicity, incidence and severity of acute and chronic GVHD, and relapse of disease
|
62 |
All |
4 Years to 75 Years (Child, Adult, Senior) |
NCT03173937 |
170091 17-H-0091 |
|
June 13, 2017 |
April 29, 2021 |
April 30, 2021 |
June 2, 2017 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
19 |
NCT01553461 |
Recruiting |
Transplants With Unlicensed Preserved Cord Blood |
- Myelodysplastic Syndrome (MDS)
- Hematologic Neoplasms
- Hematologic Diseases
- Severe Aplastic Anemia
|
- Procedure: Cord Blood Transplant
|
Interventional |
Phase 1 Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To examine the incidence of neutrophil recovery of greater than or equal to 500/mm (3) after unlicensed CBU transplant.
- Assess incidence of graft rejection, transmission of infection, serious infusion reactions.
- Determine 1 year survival.
- Assess cumulative incidence of acute GVHD (grades II to IV), (grades III to IV), and incidence of chronic GVHD.
|
500 |
All |
up to 99 Years (Child, Adult, Senior) |
NCT01553461 |
120064 12-H-0064 |
|
February 2, 2012 |
October 20, 2036 |
October 20, 2036 |
March 14, 2012 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
20 |
NCT00106925 |
Recruiting |
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants |
- Graft vs Leukemia
- Graft vs Host Disease
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Other
|
|
9999 |
All |
2 Years to 80 Years (Child, Adult, Senior) |
NCT00106925 |
050130 05-H-0130 |
|
March 30, 2005 |
|
|
April 1, 2005 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
21 |
NCT03077542 |
Recruiting |
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease |
|
- Procedure: haploidentical stem cell transplant
- Drug: sirolimus
- Drug: campath
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The percentage of patients at 100 days (+/- 1 week) post-transplantwith sustained donor type hemoglobin on hemoglobin electrophoresis (HbS less than 50% when donors have sickle cell trait and <10% when donors have normal hemoglobin), who d...
- The level of chimerism required to maintain both graft survival as well as hematologic normalcy.
|
88 |
All |
2 Years to 80 Years (Child, Adult, Senior) |
NCT03077542 |
170069 17-H-0069 |
|
April 6, 2017 |
September 30, 2025 |
August 31, 2026 |
March 13, 2017 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
22 |
NCT01861093 |
Recruiting |
Safety Study of Cord Blood Units for Stem Cell Transplants |
- Aplastic Anemia
- Leukemia
- Myelodysplastic Syndrome (MDS)
- Lymphoma
|
- Procedure: Cord Blood Units
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- (and 2 more...)
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Examine the safety of administration of the unlicensed investigational NCBP HPC-CORD Blood products
|
500 |
All |
Child, Adult, Senior |
NCT01861093 |
130116 13-H-0116 |
|
May 21, 2013 |
November 30, 2037 |
November 30, 2037 |
May 23, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
23 |
NCT02105766 |
Recruiting |
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure |
- Sickle Cell Disease
- Thalassemia
- Stem Cell Transplantation
- Graft vs Host Disease
|
- Drug: Alemtuzumab
- Drug: Sirolimus
- Drug: Cyclophosphamide
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine regimen failure rate, defined as graft rejection, severe GVHD (acute GVHD grade 3 or higher or extensive chronic GVHD), or prolonged donor red cell aplasia ( greater than 2 years post -HSCT)
- Examine the level of chimerism required to maintain both graft survival as well as hematologic normalcy using a regimen containing pentostatin, cyclophosphamide, alemtuzumab, and low total body irradiation.
|
162 |
All |
16 Years to 80 Years (Child, Adult, Senior) |
NCT02105766 |
140077 14-H-0077 |
|
April 1, 2014 |
August 31, 2021 |
August 31, 2021 |
April 7, 2014 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
24 |
NCT00003838 |
Recruiting |
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow |
- Hematologic Disease
- Lymphoma
- Multiple Myeloma
- (and 2 more...)
|
- Procedure: Stem cell transplantation
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate engraftment by bone marrow chimerism analysis.
- To determine the incidence and severity of acute and chronic graft-versus-host disease (GVHD).
|
214 |
All |
2 Years to 80 Years (Child, Adult, Senior) |
NCT00003838 |
990050 99-H-0050 |
|
February 23, 1999 |
December 1, 2019 |
December 1, 2019 |
January 27, 2003 |
April 20, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
25 |
NCT01174108 |
Recruiting |
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells |
- Severe Aplastic Anemia
- MDS (Myelodysplastic Syndrome)
|
- Device: Miltenyi CD34 Reagent System
- Other: Donor derived G-CSF mobilized PBC
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary endpoint of this study is chronic GVHD by one year.
- Transplant related mortality, engraftment, degree of donor-host chimerism, incidence of acute and chronic graft versus host disease (GVHD), transplant related morbidity and overall survival.
|
117 |
All |
4 Years to 80 Years (Child, Adult, Senior) |
NCT01174108 |
100154 10-H-0154 |
|
July 30, 2010 |
June 30, 2019 |
June 30, 2020 |
August 3, 2010 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - University of Maryland at Baltimore/MPRC
Catonsville, Maryland, United States
|
26 |
NCT00604201 |
Recruiting |
Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome |
- Myelodysplastic Syndrome (MDS)
- Severe Aplastic Anemia (SAA)
|
- Other: Umbilical Cord Blood
- Other: Haploidentical Stem Cells
- Device: Miltenvi CliniMACs CD34 Reagent System
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Day 42 cord engraftment
- 200 day treatment related mortality (TRM) and standard transplant outcome variables (non-hematological toxicities, incidence and severity of acute and chronic GVHD, and relapse of disease)
|
100 |
All |
4 Years to 75 Years (Child, Adult, Senior) |
NCT00604201 |
080046 08-H-0046 |
|
January 7, 2008 |
June 30, 2018 |
December 31, 2018 |
January 30, 2008 |
April 3, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
27 |
NCT00001529 |
Recruiting |
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives |
- Graft vs Host Disease
- Healthy
- Lymphopenia
|
|
Interventional |
Phase 1 |
- National Heart, Lung, and Blood Institute (NHLBI)
- New York University and New York Genome Center
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Enumeration of laboratory studies using collected primitive hematopoietic cells and immune effector cells.
|
99999999 |
All |
18 Years to 60 Years (Adult) |
NCT00001529 |
960049 96-H-0049 |
|
March 14, 1996 |
May 1, 2030 |
May 1, 2030 |
November 4, 1999 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
28 |
NCT02669251 |
Recruiting |
AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation |
- Chronic Graft vs Host Disease
- Chronic Graft-Versus-Host-Disease
- Bronchiolitis Obliterans Syndrome
|
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Optimal biologic dose (OBD) based on maximal NE inhibition measured in sputum
- To determine the clinical efficacy of AZD9668 at the OBD in patients with BOS after SCT
- determine the safety of AZD9668
- (and 6 more...)
|
34 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02669251 |
160060 16-C-0060 |
|
January 29, 2016 |
September 30, 2018 |
September 30, 2019 |
February 1, 2016 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
29 |
NCT00061568 |
Recruiting |
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias |
- Congenital Hemolytic Anemia
- Diamond-Blackfan Anemia
|
- Procedure: Radiotherapy
- Drug: Alemtuzumab (Campath )
- Drug: Sirolimus (Rapamune )
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
- Rate of engraftment
- The chimeric status of patients will be measured on days, +30, +60 and +100 by microsatellite analysis of the peripheral blood. More frequent monitoring may be required.
- Incidence of acute and chronic GVHD or relapse rate. GvHD or relapse together count together toward the combined endpoint for regimen failure
- (and 5 more...)
|
150 |
All |
2 Years to 80 Years (Child, Adult, Senior) |
NCT00061568 |
030170 03-H-0170 |
|
May 23, 2003 |
January 31, 2019 |
January 31, 2019 |
May 29, 2003 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
30 |
NCT02892266 |
Recruiting |
Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients |
- Solid Organ Transplant Recipients
- Parent(s)/Guardian of Referenced Transplant Recipients
|
- Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Clinical Trials in Organ Transplantation in Children
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Medication Level Variability Index (MLVI)
- University of California at Los Angeles Post-Traumatic Stress Disorder Reaction Index DSM-5 (UCLA PTSD RI DSM-5) Total Score
- Above-threshold Medication Level Variability Index (MLVI)
- (and 14 more...)
|
120 |
All |
12 Years to 17 Years (Child) |
NCT02892266 |
DAIT CTOTC-11 |
CTOTC-11 |
September 2016 |
December 2018 |
December 2018 |
September 8, 2016 |
June 14, 2017 |
|
- Ronald Reagan UCLA Medical Center: Pediatric Transplantation
Los Angeles, California, United States - Lucile Salter Packard Children's Hospital at Stanford: Pediatric Transplantation
Palo Alto, California, United States - UCSF Benioff Children's Hospital: Pediatric Transplantation
San Francisco, California, United States - (and 11 more...)
|
31 |
NCT02728102 |
Recruiting |
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) |
|
- Procedure: Tumor Cell Collection
- Procedure: Autologous Stem Cell Transplant
- Drug: Melphalan
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- Blood and Marrow Transplant Clinical Trials Network
- National Cancer Institute (NCI)
- (and 2 more...)
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Response to treatment
- Myeloma Progression
- (and 6 more...)
|
188 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02728102 |
BMTCTN1401 U01HL069294 |
|
July 2016 |
August 2020 |
August 2022 |
April 5, 2016 |
August 31, 2017 |
|
- Emory University
Atlanta, Georgia, United States - University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, United States - Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute
Boston, Massachusetts, United States - (and 13 more...)
|
32 |
NCT02440464 |
Recruiting |
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) |
|
- Procedure: Allogeneic HSCT
- Drug: Fludarabine
- Drug: Melphalan
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- Blood and Marrow Transplant Clinical Trials Network
- National Cancer Institute (NCI)
- (and 2 more...)
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-Free Survival
- Incidence of Acute GVHD (Grades II-IV)
- Incidence of Acute GVHD (Grades III-IV)
- (and 8 more...)
|
138 |
All |
18 Years to 65 Years (Adult) |
NCT02440464 |
BMTCTN1302 U01HL069294-05 |
|
August 2015 |
March 2021 |
March 2023 |
May 12, 2015 |
August 29, 2017 |
|
- City of Hope National Medical Center
Duarte, California, United States - University of California San Diego Medical Center
La Jolla, California, United States - H. Lee Moffitt Cancer Center
Tampa, Florida, United States - (and 32 more...)
|